Carboplatin + Palifosfamide-tris + Etoposide + Carboplatin
Phase 3UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-Stage Small Cell Lung Cancer
Conditions
Extensive-Stage Small Cell Lung Cancer
Trial Timeline
May 1, 2012 → Jun 1, 2015
NCT ID
NCT01555710About Carboplatin + Palifosfamide-tris + Etoposide + Carboplatin
Carboplatin + Palifosfamide-tris + Etoposide + Carboplatin is a phase 3 stage product being developed by Alaunos Therapeutics for Extensive-Stage Small Cell Lung Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT01555710. Target conditions include Extensive-Stage Small Cell Lung Cancer.
What happened to similar drugs?
0 of 6 similar drugs in Extensive-Stage Small Cell Lung Cancer were approved
Approved (0) Terminated (1) Active (5)
🔄Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)Bristol Myers SquibbPhase 3
🔄BMS-986489 (BMS-986012+Nivolumab) + Atezolizumab + Carboplatin + EtoposideBristol Myers SquibbPhase 3
Hype Score Breakdown
Clinical
17
Activity
4
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01555710 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Extensive-Stage Small Cell Lung Cancer